Mylan Launches Generic Hepatitis B Treatment
Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.
Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.
This announcement follows the FDA’s final approval of Mylan’s Abbreviated New Drug Application for the product, which is indicated for the treatment of chronic HBV infection associated with evidence of hepatitis B viral replication and active liver inflammation.
Mylan’s version of lamivudine will be available in 100 mg tablets, which had approximately $18.1 million worth of sales in the United States for the 12 months ending September 30, 2014, according to IMS Health.
